Clinical Trials
1,819 trialsBuMelMCRN001
University Health Network, Toronto
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Stanford University
AMYLOCARP
Ramsay Générale de Santé
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
CArdiag
Lantheus Biosciences Ltd.
ZFAS1-BIPN
The First Affiliated Hospital of Zhejiang Chinese Medical University
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
POM MM 014
Celgene
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
COSMIC
ASH Research Collaborative
IFM2009-02
University Hospital, Lille
KIRMONO
Innate Pharma
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
KEYNOTE145
Acerta Pharma BV
UNIVERSAL
Allogene Therapeutics
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Fondazione IRCCS Policlinico San Matteo di Pavia
MYELOCHOL
University Hospital, Bordeaux
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Ciusss de L'Est de l'Île de Montréal
iPREFER
The Christie NHS Foundation Trust
A Real-world Study in Participants With Smoldering Multiple Myeloma
Janssen-Cilag Ltd.
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
DREAMM 14
GlaxoSmithKline
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
National Institutes of Health Clinical Center (CC)
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
University of Alabama at Birmingham
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
DELICATESSE
Nantes University Hospital
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
FORTE
University of Turin, Italy
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
Hoffmann-La Roche
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Flu-Mel-Vel
Hackensack Meridian Health
IFM-CRd
University Hospital, Toulouse
IFM2012-03
University Hospital, Lille
IFM2014-04
University Hospital, Lille
IFM2005-02
University Hospital, Toulouse
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Beth Israel Deaconess Medical Center